Tandem Diabetes Care

Tandem Diabetes Care is a medical device company with an innovative, user-centric and integrated approach to the design, development, and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells a family of insulin pump products, which includes the t:slim X2™ Insulin Pump, the next-generation color touchscreen pump, the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements, and the t:slim G4™ Insulin Pump, the first CGM-enabled pump with touch-screen simplicity.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
2006
Size (employees)
591 (est)
Tandem Diabetes Care was founded in 2006 and is headquartered in San Diego, US

Key People at Tandem Diabetes Care

Kim D. Blickenstaff

Kim D. Blickenstaff

President , CEO & Board Of Director
John Cajigas

John Cajigas

CFO
Jim Leal

Jim Leal

VP, Operations
Bob Anacone

Bob Anacone

EVP and Chief Commercial Officer
Susan Morrison

Susan Morrison

VP, HR, Corporate & Investor Relations

Tandem Diabetes Care Office Locations

Tandem Diabetes Care has an office in San Diego
San Diego, US (HQ)
11045 Roselle St

Tandem Diabetes Care Data and Metrics

Tandem Diabetes Care Financial Metrics

Tandem Diabetes Care's revenue was reported to be $19 m in Q1, 2017
USD

Revenue (Q1, 2017)

19 m

Gross profit (Q1, 2017)

6.8 m

Gross profit margin (Q1, 2017), %

36%

Net income (Q1, 2017)

(23.8 m)

EBIT (Q1, 2017)

(21.2 m)

Market capitalization (17-Aug-2017)

31.1 m

Cash (31-Dec-2016)

44.7 m

EV

65.4 m
Tandem Diabetes Care's current market capitalization is $31.1 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

49.7 m72.9 m84.2 m

Revenue growth, %

47%16%

Cost of goods sold

34.5 m46.3 m60.7 m

Gross profit

15.2 m26.6 m23.6 m

Gross profit Margin, %

31%36%28%

Operating expense total

90.9 m95.6 m101.6 m

EBIT

(75.7 m)(69 m)(78.1 m)

EBIT margin, %

(152%)(95%)(93%)

Net Income

(79.5 m)(72.4 m)(83.4 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

15.7 m15.7 m20.1 m23 m12.3 m19 m

Cost of goods sold

10.9 m10.2 m13.1 m14.8 m13.9 m12.2 m

Gross profit

4.8 m5.5 m6.9 m8.2 m(1.6 m)6.8 m

Gross profit Margin, %

31%35%35%36%(13%)36%

R&D expense

3.9 m5.1 m4.2 m4.1 m6.2 m5.1 m

General and administrative expense

19.6 m19.1 m22 m21.1 m20.7 m22.8 m

Operating expense total

23.5 m24.2 m26.2 m25.2 m26.8 m28 m

EBIT

(18.7 m)(18.7 m)(19.2 m)(17.1 m)(28.4 m)(21.2 m)

EBIT margin, %

(119%)(119%)(96%)(74%)(231%)(112%)

Net Income

(19.5 m)(19.6 m)(20.5 m)(18.3 m)(29.8 m)(23.8 m)
USDFY, 2014FY, 2015FY, 2016

Cash

31.2 m43.1 m44.7 m

Accounts Receivable

7.7 m14.1 m11.2 m

Inventories

11.9 m17.5 m21.2 m

Current Assets

90.8 m107 m92.1 m

PP&E

12.6 m15.5 m18.4 m

Total Assets

106.5 m125.1 m112.4 m

Accounts Payable

1.9 m5.2 m7.5 m

Total Debt

29.4 m29.3 m79 m

Current Liabilities

18.1 m26.5 m31.5 m

Non-Current Liabilities

33.8 m34.7 m86.8 m

Total Liabilities

51.9 m61.3 m118.3 m

Additional Paid-in Capital

303.3 m384.6 m398.6 m

Retained Earnings

(248.7 m)(321.1 m)(404.6 m)

Total Equity

33.8 m63.5 m(5.9 m)

Debt to Equity Ratio

0.9 x0.5 x-13.3 x

Debt to Assets Ratio

0.3 x0.2 x0.7 x

Financial Leverage

3.2 x2 x-19 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(79.5 m)(72.4 m)(83.4 m)

Depreciation and Amortization

4.4 m4.8 m5.5 m

Accounts Receivable

(2.5 m)(6.5 m)2.3 m

Inventories

(1.8 m)(6.1 m)(6.9 m)

Accounts Payable

(1.2 m)3.4 m3.2 m

Cash From Operating Activities

(61.4 m)(58.8 m)(61.2 m)

Purchases of PP&E

(4.4 m)(5.8 m)(8.9 m)

Cash From Investing Activities

(35.5 m)2.4 m10.4 m

Short-term Borrowings

(30 m)(30 m)

Cash From Financing Activities

3.6 m68.3 m52.3 m

Interest Paid

3.4 m3.3 m4.4 m

Income Taxes Paid

71 k9 k23 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(19.5 m)(19.6 m)(20.5 m)(18.3 m)(29.8 m)(23.8 m)

Accounts Receivable

4.4 m5.8 m5.2 m7.5 m7 m9.1 m9.4 m8.2 m7.7 m

Inventories

11.1 m11.9 m14.7 m17.6 m20.2 m21.7 m22.9 m

Accounts Payable

2.5 m3 m4.1 m4 m4 m6 m6.8 m5.6 m4.9 m
USDY, 2017

EV/EBIT

-3.1 x

Revenue/Employee

32.1 k

Tandem Diabetes Care Operating Metrics

Tandem Diabetes Care's Devices Sold was reported to be 50 k in FY, 2016
FY, 2016

Devices Sold

50 k

Patents Issued

50

Patents Pending

46

Trademarks

23

Tandem Diabetes Care Market Value History

Traffic Overview of Tandem Diabetes Care

Tandem Diabetes Care Online and Social Media Presence

Tandem Diabetes Care Company Life and Culture

You may also be interested in